QualityStocks would like to highlight BIOLASE, Inc. (
NASDAQ: BIOL). The company is revolutionizing surgery in dentistry and medicine with WaterLase technology. They specialize in the development, manufacturing, and marketing of lasers and related products to provide biological treatments that eliminate pain and are safer for patients. The company leads the global dental industry with their flagship, best-selling laser systems such as the WaterLase iPlus™ and WaterLase MDX™, which both feature novel, patented laser technologies designed by BIOLASE's R&D and clinical teams to perform dental and medical surgery, while dramatically reducing pain and improving clinical results.
In the company’s news,
BIOLASE announced that the U.S. Patent and Trademark Office issued it a new patent covering the use of its laser technologies for treating various conditions of the eye, including cataracts, glaucoma, and presbyopia. The patent significantly broadens the claims for the patent family and anticipates using complimentary technologies to streamline procedures to identify the rigidity of the eye to optimize treatment locations in presbyopia procedures, for example.
The latest patent grant is the tenth U.S. patent issued under the “Methods for Treating Eye Conditions” patent family. Three other patents have been issued internationally and six more are pending worldwide. BIOLASE now holds a total of 20 issued and 20 pending U.S. and international patents in seven patent families in the field of ophthalmology. The patents give the company and its OCCULASE subsidiary a wide range of potential applications and coverage in the field.
This new patent is important for the company and its innovative WaterLase technology. Marcia Van Valen, director of business development for BIOLASE, said the patent further leverages the firm’s technology and broadens the patent family “to allow the laser parameters and groupings of tissue treatment to compensate for correlation in the various layers in ocular tissue for treating eye conditions such as presbyopia, cataract and glaucoma.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
